Jordan P Metcalf
Overview
Explore the profile of Jordan P Metcalf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
878
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jayavelu N, Samaha H, Wimalasena S, Hoch A, Gygi J, Gabernet G, et al.
medRxiv
. 2025 Feb;
PMID: 39990570
The post-acute sequelae of SARS-CoV-2 (PASC), also known as long COVID, remain a significant health issue that is incompletely understood. Predicting which acutely infected individuals will go on to develop...
2.
Gabernet G, Maciuch J, Gygi J, Moore J, Hoch A, Syphurs C, et al.
bioRxiv
. 2025 Feb;
PMID: 39990442
Following SARS-CoV-2 infection, ~10-35% of COVID-19 patients experience long COVID (LC), in which often debilitating symptoms persist for at least three months. Elucidating the biologic underpinnings of LC could identify...
3.
Wang K, Nie Y, Maguire C, Syphurs C, Sheen H, Karoly M, et al.
bioRxiv
. 2024 Dec;
PMID: 39651165
Hospitalized COVID-19 patients exhibit diverse immune responses during acute infection, which are associated with a wide range of clinical outcomes. However, understanding these immune heterogeneities and their links to various...
4.
Maguire C, Chen J, Rouphael N, Pickering H, Phan H, Glascock A, et al.
bioRxiv
. 2024 Nov;
PMID: 39605478
Chronic viral infections are ubiquitous in humans, with individuals harboring multiple latent viruses that can reactivate during acute illnesses. Recent studies have suggested that SARS-CoV-2 infection can lead to reactivation...
5.
Lehmann M, Krishnan R, Sucre J, Kulkarni H, Pineda R, Anderson C, et al.
Am J Respir Cell Mol Biol
. 2024 Nov;
PMID: 39499861
The urgent need for effective treatments for acute and chronic lung diseases underscores the significance of developing innovative preclinical human research tools. The 2023 ATS Workshop on Precision Cut Lung...
6.
Wu W, Alexander J, Booth J, Miller C, Metcalf J, Drevets D
Immun Ageing
. 2024 Jun;
21(1):39.
PMID: 38907247
Background: Age > 65 years is a key risk factor for poor outcomes after human influenza infection. Specifically, in addition to respiratory disease, non-neurotropic influenza A virus (IAV) causes neuro-cognitive...
7.
Gygi J, Maguire C, Patel R, Shinde P, Konstorum A, Shannon C, et al.
J Clin Invest
. 2024 May;
134(9).
PMID: 38690733
BACKGROUNDPatients hospitalized for COVID-19 exhibit diverse clinical outcomes, with outcomes for some individuals diverging over time even though their initial disease severity appears similar to that of other patients. A...
8.
Gandikota C, Vaddadi K, Sivasami P, Huang C, Liang Y, Pushparaj S, et al.
J Med Virol
. 2024 Apr;
96(4):e29579.
PMID: 38572923
Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) primarily targets the respiratory system. Physiologically relevant human lung models are indispensable to investigate virus-induced host response and disease pathogenesis. In this study,...
9.
Ozonoff A, Jayavelu N, Liu S, Melamed E, Milliren C, Qi J, et al.
Nat Commun
. 2024 Jan;
15(1):216.
PMID: 38172101
Post-acute sequelae of SARS-CoV-2 (PASC) is a significant public health concern. We describe Patient Reported Outcomes (PROs) on 590 participants prospectively assessed from hospital admission for COVID-19 through one year...
10.
Ozonoff A, Schaenman J, Jayavelu N, Milliren C, Calfee C, Cairns C, et al.
EBioMedicine
. 2023 Nov;
98:104860.
PMID: 37918220
No abstract available.